Fidelity SPDR Advertisement
Home > Boards > Stock Clubs > Market Trends and Strategies > Monk's Den

PATER NOSTER, qui es in caelis,sanctificetur nomen tuum.Adveniat

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
righty Member Profile
 
Followed By 246
Posts 26,818
Boards Moderated 13
Alias Born 06/14/06
160x600 placeholder
Roche Hit By Failure Of Cancer Drug Trial
Roche said a late-stage study of its breast cancer drug Kadcyla failed to yield superior results to an existing treatment, damaging the outlook for stronger sales in one of its key drug markets.
More Top Equities Stories Of The Day
Deezer Names New CEO Before Full U.S. Launch
How a Memo Cost Big Banks $37 Billion
Liberty Media's CommerceHub Acquires E-Commerce Adviser Mercent
Nike Sees Jump in Sales, Growth Concerns -- 4th Update
ADR Shares End Lower; BT Group Shares Trade Actively
Joy Global's Joyless Year -- Ahead of the Tape
Hungary to Sell MKB Bank After Revamp by Central Bank - Prime Minister
Norway Central Bank to Decide Oil Fund Exclusions
righty   Saturday, 03/28/09 11:00:14 AM
Re: Monk post# 45033
Post # of 319093 
PATER NOSTER, qui es in caelis,sanctificetur nomen tuum.Adveniat regnum tuum.Fiat voluntas tua, sicut in caelo et in terra.Panem nostrum quotidianum da nobis hodie,et dimitte nobis debita nostra,sicut et nos dimittimus debitoribus nostris.Et ne nos inducas in tentationem:sed libera nos a malo. Amen.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist